Many insiders treat options as 'found money'. when the prices go up they get nervous like everyone else. if they're selling on inside information that is easily traceable to their knowlledge of approvals, lawsuits or anything else underhanded, they'll have bigger worries than losing a few dollars. my guess it that they believe that anything they give up here on the sale of their options will be returned to them in future appreciation of other opttions. who knows maybe a beach house or other vacation spot is available and they need the money now, not a couple of years from now.
hard to say why selling is going on. perhaps to get money for lower cost options or maybe they need the money. I don't follow this indicator anymore. I've sold too many companies on the thought that insiders knew what they were doing in selling. many don't even know the potential of their own companies. I recall vividly when insiders sold ISRG at $17/share. It went to the moon without me because I followed the dummies' lead and sold my 200 shares, too.
probably because Google is in no hurry to release. so, ALSO is dead until that happens. Another reason is that you can't sell this stock after you buy it unless you want to lose 10-15%. Buy all you want but be prepared to give up a substantial part when selling.
I'd like to be able to help you on this, but ALSO keeps adding folks who want a salary and provide nothing on the revenue side. I own a few thousand shares but don't expect too much here. If I can get 50% return I'm gone. I do own VUZI a company that already is selling these type devices. If you have patience VUZI bounces around from $2.50 - $3.10 pricewise. They are ramping up right now in Europe. This is my play in this space. Take a look MZOR and SWIR for long term.
Yes I have DDD and PRLB. DDD is fairly local to me so I caught them early on. The recent pullback doesn't bother me too much. I sold enough in the 80's to be on 'house' money now. As for PRLB they are unique because they make individual parts as needed. They are going international now, so I like them to continue to do well. Never did have SSYS, XONE or the other one--can't remember the name.
I always wait 1-2 months after Motley Fool recommends something. They do articles to sell subscriptions. The same 'internet of things' article has been running for at least 2 months and the price rose and then fell. I'm sure there are folks making money off both directions. Mid teens are looking like a real possibility unless news is forthcoming. NXPI is the company that is likely to make a boatload of money.
Apparently, there are no workers @ALSO, only chiefs. They are constantly adding salary sponges to the company. I don't expect this stock to be much more than a trading stock because the flow of any earnings will go to the chiefs. You might want to look at VUZI which has a AR product that is actually working now.
I too have HIMX from $5 to now, MZOR from $10 to now. I like PSDV long-term and ALIM both of which I have held since the low $2's. My biggest screw up. Selling NXPI at $27. Maybe I'll get a second chance.
We'll know by late April about BK, unless there is short term funding that shows up. If no revenues by April then it's kaput.
They do know where their bread is buttered. When the gov't shutdown occurred a backlog was created. Recall that the decision was delayed because the FDA folks weren't working. When there is a backlog the most important items get shuffled to the front when you return to work. 'Most important' meaning those things that have a huge price associated with them (political, economic, on-going relationships, etc). PSDV and ALIM got caught in the shuffle and the FDA had to make a quick decision, so they shot them down. Of course, they looked like idiots with the British, Germans, Spanish, French et al already approving the drug. So the pivot. Hey, it happens. If you want to blame anyone I recommend starting with the tea party crackpots who stupidly thought they could accomplish with their methods what no one else wanted to accomplish.
FDA is only the United States. Europe, Canada, Japan and Korea move at their own pace. The FDA has a history of slowing down useful drugs/products/procedures for whatever reason they wish most of the time tied to the politically well-connected behemoths. Witness PSDV and ALIM. Already approved in most of the Europe, Canada, Australia, Japan, the FDA slammed the door on ALIM's product in the US this past October. However, a 'reconsideration' of the FDA's hasty behavior recently will now let Americans receive the benefits of these companies efforts.
I doubt you'll see $15 until a 3/2 split or better split.
you're right they're never making a dime. And now another 23 M to spread around. to the various spots on the globe. Don't waste too much money on this company's stock. Unless you want to offset a gain on another stock with the losses you'll be taking on this one. Buy SWIR, MZOR, HIMX for long term gains.
I agree---after a 1 : 2 stock split. with all the great companies out there it's odd that people are choosing to invest in this outfit. Look at the chart. You'd be better off in Las Vegas even if you're drunk at the table. Look at MZOR, MITK, ALSO and HIMX. At least 2 will boom and none will perform like LIME.